Drug-induced liver injury from antiepileptic drugs

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 687-697

  Au, Jennifer S ^a   Pockros, Paul J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

Antiepileptic drugs; Drug induced liver injury; Hepatotoxicity

Indexed keywords

ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; FELBAMATE; GAMMA GLUTAMYLTRANSFERASE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ACUTE LIVER FAILURE; ALKALINE PHOSPHATASE BLOOD LEVEL; APLASTIC ANEMIA; ATONIC SEIZURE; BIPOLAR DISORDER; BRAIN DISEASE; DATA BASE; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; EOSINOPHILIA; EPILEPSY; EPILEPTIC STATE; FATIGUE; FEBRILE CONVULSION; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; HYPERTHERMIA; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHADENOPATHY; MIGRAINE; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS;

ANTIEPILEPTIC DRUGS; DRUG-INDUCED LIVER INJURY; HEPATOTOXICITY;

ANTICONVULSANTS; DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84884942175     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.011     Document Type: Review

References (69)

1. Larry D. Epidemiology and individual susceptibility to adverse drug reaction affecting the liver. Semin Liver Dis 2002, 22:145-155.
2. Chang B.S., Lowenstein D.H. Epilepsy. NEngl J Med 2003, 349:1257-1266.
3. Brodie M.J. Antiepileptic drug therapy the story so far. Seizure 2010, 19(10):650-655.
4. Bialer M. Chemical properties of antiepileptic drugs. Adv Drug Deliv Rev 2012, 64:887-895.
5. Engel J. Surgery for seizures. NEngl J Med 1996, 334:647-653.
6. Stahl S.M. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. JClin Psychiatry 2004, 65:738-739.
7. Loscher W. Invivo administration of valproate reduced the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci Lett 1993, 160:177-180.
8. Silva M.F., Aires C.C., Luis P.B., et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. JInherit Metab Dis 2008, 31:205-216.
9. Morland C., Nordengen K., Gundersen V. Valproate causes reduction of the excitatory amino acid aspartate in nerve terminals. Neurosci Lett 2012, 527:100-104.
10. Nalivaeva N.N., Belyaev N.D., Turner A.J. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 2009, 30:509-514.
11. Baillie T.A., Levy R. Metabolic fate of valproid acid in humans. Idiosyncratic reactions to valproate 1991, 19-24. Raven, New York. R.H. Levy, J.K. Penry (Eds.).
12. Cotariu D., Zaidman J.L. Valproic acid and the liver. Clin Chem 1988, 34:890-897.
13. Chicharro A.V., Marinis A.J., Kanner A.M. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist. Epilepsy Behav 2007, 11:361-366.
14. Dealberto M.J. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007, 22:330-337.
15. Wadzinski J., Franks R., Roane D., et al. Valproate-associated hyperammonemic encephalopathy. JAm Board Fam Med 2007, 20:499-502.
16. Willmore L.J. Clinical manifestations of valproate hepatotoxicity. Idiosyncratic reactions to valproate 1991, 3-6. Raven, New York. R.H. Levy, J.K. Penry (Eds.).
17. Dreifuss F.E., Santilli N., Langer D.H., et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987, 37:379-385.
18. Koenig S.A., Buesing D., Longin E., et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47:2027-2031.
19. Dreifuss F.E., Langer D.H., Moline K.A., et al. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989, 39:201-207.
20. Bryant A.E., Dreifuss F.E. Valproic acid hepatic fatalities III US experience since 1986. Neurology 1996, 46:465-469.
21. Schmid M.M., Freudenmann R.W., Keller F., et al. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 2012, 46:36-38.
22. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic Injury: analyses of 23 fatal cases. Hepatology 1982, 2:591-597.
23. Pockros P.J., Esrason K.T. Microvesicular fat diseases of the liver. Bockus gastroenterology 1995, 2254-2275. W.B. Saunders Co, Philadelphia. 5th edition. W.S. Haubrich, F. Schaffner (Eds.).
24. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol 2009, 47:101-111.
25. Porter R.J. Antiepileptic drugs:efficacy and inadequacy. New anticonvulsant drugs 1986, 3-15. John Libby, London. 4th edition. B.S. Meldrum, R.J. Porter (Eds.).
26. Walker M. Status epilepticus: an evidence based guide. BMJ 2005, 331:673-677.
27. Bajpai M., Roskos L.K., Shen D.D., et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996, 24(12):1401-1403.
28. Spielberg P., Gordon G.B., Blake D.A., et al. Predisposition to phenytoin hepatotoxicity assessed invitro. NEngl J Med 1981, 305:722-727.
29. Aiges H.W., Daum F., Olson M., et al. The effects of phenobarbital and diphenylhydantoin on liver function and morphology. JPediatr 1980, 97:22-26.
30. Farrell O.C. Drug-induced liver disease 1994, Churchill Livingston, London.
31. Bjornsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007, 25:1411-1421.
32. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
33. Vittorio C.C., Muglia J.J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995, 27:2285-2290.
34. Chua H.C., Venketasubramanian N., Tjia H., et al. Elimination of phenytoin in toxic overdose. Clin Neurol Neurosurg 2000, 102:6-8.
35. Sen S., Ratnaraj N., Davies N.A., et al. Treatment of phenytoin toxicity by molecular adsorbents recirculating system (MARS). Epilepsia 2003, 44:265-267.
36. Frenchie D., Bastani B. Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. Nephrol Dial Transplant 1998, 13:817-818.
37. Bernus I., Dickinson R.G., Hooper W.D., et al. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res 1996, 24:163-172.
38. Park B.K., Kitteringham N.R., Powell H., et al. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000, 153:39-60.
39. Leeder J.S., Pirmohamed M. Anticonvulsant agents. Drug induced liver disease 2003, 425-446. Marcel Decker, Inc, New York. N. Kaplowitz, L.D. DeLeve (Eds.).
40. Lu W., Uetrecht J.P. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab Dispos 2008, 36:1624-1636.
41. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reaction. Lancet 1999, 353:2190-2194.
42. Pirmohamed M., Lin K., Chadwick D., et al. TNF alpha promoter region gene polymorphisms in CBZ- hypersensitive patients. Neurology 2001, 56:890-896.
43. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
44. Ashmark H., Wilholm B. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990, 81:131-140.
45. Benedetti M.S., Ruty B., Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 2005, 19:511-529.
46. Forbes G.M., Jeffrey G.P., Shilkin K.B., et al. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992, 102:1385-1388.
47. Ramos A.M., Gayotto L.C., Clemente C.M., et al. Reversible vanishing bile duct syndrome induced by carbamazepine. Eur J Gastroenterol Hepatol 2002, 14:1019-1022.
48. Mitchell M.C., Boinott J.K., Arregui A., et al. Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 1981, 71:733-735.
49. Levy M., Goodman M.W., Van Dyne B.J., et al. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981, 95:64-65.
50. Brodie M.J. Lamotrigine. Lancet 1992, 339:1397-1400.
51. Besag F.M., Wallace S.J., Dulac O., et al. Lamotrigine for the treatment of epilepsy in childhood. JPediatr 1995, 127:991-997.
52. Maggs J.L., Naisbitt D.J., Tettey J.N., et al. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000, 13:1075-1081.
53. Ouellet G., Tremblay L., Marleau D. Fulminant hepatitis induced by lamotrigine. South Med J 2009, 102:82-84.
54. Fix O.K., Peters M.G., Davern T.J. Eosinophilic hepatitis caused by lamotrigine. Clin Gastroenterol Hepatol 2006, 4:xxvi.
55. Fayad M., Choueiri R., Mikati M. Potential hepatotoxicity of lamotrigine. Pediatr Neurol 2000, 22:49-52.
56. Sauve G., Bresson-Hadni S., Prost P., et al. Acute hepatitis after lamotrigine administration. Dig Dis Sci 2000, 45:1874-1877.
57. Overstreet K., Costaanza C., Behling C., et al. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci 2002, 47:1921-1925.
58. Amante M.F., Filippini A.V., Cejas N., et al. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol 2009, 8:75-77.
59. Su-Yin A.N., Tai W.W., Olson K.R. Lamotrigine-associated reversible severe hepatitis: a case report. JMed Toxicol 2008, 4:258-260.
60. Moeller K.E., Wei L., Jewell A.D., et al. Acute hepatotoxicity associated with lamotrigine. Am J Psychiatry 2008, 165:539-540.
61. Kwan P., Brodie M. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004, 45:1141-1149.
62. Shapiro P.A., Antonioli D.A., Peppercorn M.A. Barbiturate-induced submassive hepatic necrosis. Am J Gastroenterol 1980, 74:270-273.
63. Pellock J.M., Brodie M.J. Felbamate: 1997 update. Epilepsia 1997, 38:1261-1264.
64. Li L.M., Nashef L., Moriarty J., et al. Felbamate as add-on therapy. Eur Neurol 1996, 36:146-148.
65. Pirmohamed M., Leeder S.J. Anticonvulsant agents. Drug-induced liver disease 2007, 485-506. Informa Healthcare USA, New York. 2nd edition. N. Kaplowitz, L.D. DeLeve (Eds.).
66. Dieckhaus C.M., Thompson C.D., Roller S.G., et al. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 2002, 142:99-117.
67. Lee W.M., Squires R.H., Nyberg S.L., et al. Acute liver failure: summary of a workshop. Hepatology 2008, 47:1401-1415.
68. Russo M.W., Galanko J.A., Shrestha R., et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10:1018-1023.
69. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing Database. Liver Transpl 2009, 15:719-729.